Funding Opportunity RFA-CA-22-039 from the NIH Guide for Grants and Contracts. The objectives of the Early Detection Research Network (EDRN; edrn.cancer.gov) are to discover, develop and validate biomarkers and imaging methods to detect early stage cancers and to translate these into clinical tests. The EDRN provides an infrastructure that is essential for this process and has successfully completed more than10 multicenter validation studies.

Notice NOT-HL-22-026 from the NIH Guide for Grants and Contracts

Notice NOT-HL-22-025 from the NIH Guide for Grants and Contracts

Notice NOT-DE-22-003 from the NIH Guide for Grants and Contracts

Notice NOT-CA-22-104 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-180 from the NIH Guide for Grants and Contracts

Notice NOT-HL-22-034 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-182 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-CA-22-038 from the NIH Guide for Grants and Contracts. Through this limited competition Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites applications to continue support for the Cancer Immune Monitoring and Analysis Centers Cancer Immunologic Data Center (CIMAC-CIDC) Network. The CIMAC-CIDC is a network of laboratories (CIMACs) and a bioinformatics center (CIDC) established to perform correlative studies using biospecimens from cancer immunotherapy clinical trials. Applying a comprehensive set of state-of-the-art immunoprofiling assays and bioinformatics pipelines, the CIMAC studies encompass genomics, transcriptomics, proteomics, microbiomes, and phenotyping analyses of tumor, tumor microenvironment, blood, stool, and other types of biospecimens. The ultimate goal of the CIMAC-CIDC Network is to identify biomarkers of response, resistance, and adverse events to optimize immunotherapy approaches for patients with cancer. CIMACs work with clinical trial teams and CIDC on correlative studies examining the association of biomarker data from the assays with clinical data from the trials.

Notice NOT-AA-22-014 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-22-504 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the National Heart, Lung and Blood Institute (NHLBI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), invites applications for a limited competition for the two Clinical Coordinating Centers (CCCs) already involved in The Chronic Kidney Disease in Children Study (CKiD) Consortium. The clinical centers will continue to evaluate enrolled participants, recruit new participants, and continue to work together cooperatively with the existing Data Coordinating Center (DCC) and Central Biochemistry Laboratory (CBL) of the study as a consortium.

Funding Opportunity RFA-DK-22-010 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the National Heart, Lung and Blood Institute (NHLBI) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), invites applications for the Central Biochemistry Laboratory (CBL) for the Chronic Kidney Disease in Children Study (CKiD) Consortium. The CBL will work cooperatively with the existing Clinical Coordinating Centers (CCCs) and the Data Coordinating Center (DCC) of the study as a consortium.

Funding Opportunity RFA-DK-22-505 from the NIH Guide for Grants and Contracts. The NIDDK, in collaboration with the NHLBI and NICHD, invites an application for a limited competition for the Data Coordinating Center (DCC) already involved in The Chronic Kidney Disease in Children Study (CKiD) Consortium. The DCC will work cooperatively with the existing Clinical Coordinating Centers (CCCs) and Central Biochemistry Laboratory (CBL) of the study as a consortium.

Funding Opportunity PAR-22-210 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement encourages applications using community-engaged research methods to investigate the potential health risks of environmental exposures of concern to the community and to implement an environmental public health action plan based on research findings. The overall goal is to inform and support efforts to prevent or reduce exposure to harmful environmental exposures and improve the health of a community.

Funding Opportunity RFA-OD-22-015 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this ORWH R25 program is to support educational activities that complement and/or enhance the training of a diverse workforce to meet the nations biomedical, behavioral and clinical research needs. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Curriculum or Methods Development. Specifically, this FOA will support the development of short courses, training modules, curricula, and other educational activities to enhance knowledge of sex and gender influences on health and disease among scientists, clinicians, and health professionals, and other stakeholders to accelerate the translation of that knowledge into practice.

Notice NOT-PM-22-003 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-177 from the NIH Guide for Grants and Contracts

Notice NOT-OD-22-176 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-21-031 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing the development and/or validation of targeted mass spectrometric assays (e.g. Multiple Reaction Monitoring) for proteins and peptides of primary interest to the type 1 diabetes research community [e.g. glucagon and other pro-glucagon derived peptides, C-peptide, insulin, pro-insulin, Glycated CD59, Islet Amyloid Polypeptide (IAPP), Chromogranin A (CgA), and chromogranin B (CgB)]. The proposed assays should be highly reproducible, easily transferable to other laboratories, and validated in human plasma or serum. This might also require the development of appropriate community standards, and reference materials when not already available.

Funding Opportunity PAS-22-206 from the NIH Guide for Grants and Contracts. This HEAL FOA provides an opportunity for early career researchers or early career clinicians with foundational backgrounds in addiction to develop expertise in implementation science. Successful applicants would propose training in implementation science methods, and a research project that would apply these to at least one of the four priority domains of the HHS Overdose Prevention Strategy: primary prevention (including appropriate opioid prescribing), OUD treatment, harm reduction, and/or recovery support services. The overarching goal is to build a cadre of implementation researchers who can contribute to addressing the current overdose crisis, develop research careers that will impact the quality of addiction clinical practice generally, and become the next generation of implementation experts and mentors.